

Press Release

IOTA Pharmaceuticals, KinaseDetect and SARomics Biostructures announce the formation of the KINOMED Partnership to accelerate human protein kinase drug discovery

Cambridge, UK, Odense, Denmark & Lund, Sweden, February 22, 2011 – The KINOMED Partnership, funded by the Eurostars program of the European Union, has been established to provide an integrated package of services for protein kinase inhibitor discovery and development. Kinase production, kinase assay development, kinase crystal structure determination, kinase fragment library construction, hit finding and optimisation, in silico screening, kinase biochemical and biophysical screening, structure- and ligand-based drug design and medicinal chemistry services are all included within a single, state-of-the-art offering.

“We are excited to be working with IOTA and KinaseDetect. Both companies are led by world-known researchers with impressive track records within the kinase and kinase drug discovery fields.” says Dr. Derek Logan, CSO of SARomics Biostructures.

Prof. Olaf-Georg Issinger, director of KinaseDetect, comments: “Structure-based drug design in combination with fragment-based lead discovery is a powerful combination in modern drug discovery. We are collaborating with IOTA Pharmaceuticals and SARomics Biostructures in developing a service platform to provide the pharmaceutical industry with off-the-shelf three-dimensional structures of kinases and their complexes with novel lead compounds. The provision of such an integrated service platform will greatly accelerate the drug discovery process for this important class of drugs.”

Dr. David Bailey, Director and Co-founder of IOTA, states: “Fragment-based drug discovery at IOTA combines identification of fragments with high ligand efficiency with the power of structure-based drug design, rapidly optimising ligand binding and selectivity in drug-like molecules. The KINOMED Partnership between KinaseDetect, SARomics and IOTA will develop these leads to produce a new generation of kinase therapeutics.”

IOTA Pharmaceuticals (**Error! Hyperlink reference not valid.**) was founded in late 2007 and offers services to the pharmaceutical industry in the emerging area of fragment-based drug discovery. Activities completely span the hit finding and lead optimization stages of drug development, and include target analysis, focused fragment library construction, in silico screening, biochemical and biophysical screening, structure- and ligand-based design and medicinal chemistry services.

KinaseDetect (<http://www.kinasedetect.dk>) was founded in 2001. Since 2002 recombinant protein kinases are offered to major pharmaceutical companies and to academic customers. Furthermore, kinase assays are offered as service to pharmaceutical companies and a number of projects for different companies have been carried out.

SARomics Biostructures (<http://www.saromics.com>) is the leading Scandinavian provider of structural biology and in silico drug discovery

services. The company accelerates its customers' drug discovery processes by providing contract R&D support in the areas of protein crystallization, X-ray protein structure determination, NMR spectroscopy and computational chemistry. Since its foundation in 2006 the company has successfully carried out a number of projects for companies such as Biovitrum, Active Biotech, LEO Pharma, Inimex Pharmaceuticals and others.

For further general information please visit www.kinomed.com or contact Dr. Björn Walse, Director Sales & Marketing, sales@saromics.com.

To contact KINOMED (<http://www.kinomed.com>) please use sales@kinomed.com, to obtain further information about current targets and technologies, and to obtain a specific quotation for new structure-led discovery programs.